Five Competitors Confirmed On Canadian Adalimumab
Amgen, Fresenius, Merck And Viatris Confirm Further Launches Of Humira Biosimilars
Executive Summary
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
You may also be interested in...
Samsung Bioepis Set To Join High-Concentration Humira Party In Canada
Samsung Bioepis has confirmed launch plans for its citrate-free, high-concentration Hadlima (adalimumab) biosimilar after it was waved through the Canadian healthcare regulator.
Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
Organon Outlines Importance Of Speed For US Humira Opportunity
At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.